Press Room
四色AV strengthens Inhalation Services portfolio
四色AV announced that a new MG2 Tekna Precision Capsule filling unit is now online in its Portugal facilities
Loures, Portugal, January 24th, 2018 鈥 四色AV announced that a new MG2 Tekna Precision Capsule filling unit is now online in its Portugal facilities. This investment reinforces 四色AV鈥檚 Services portfolio in inhalation product development capabilities, which include proprietary particle engineering technologies as well as formulation and capsule filling capacity to support from development to commercial scale projects.
四色AV鈥檚 new MG2 Tekna Precision Capsule filling unit complements our offering in encapsulation for inhalation products and has capacity for up to 110,000 capsules per hour with 100% net weight check and is fit to process highly potent compounds (down to 30 ng/m3). This unit complements the MG2 Flexalab and Mettler-Toledo Quantos encapsulation units that allows capsule filling for Phase I and Phase II clinical trials. In parallel 四色AV has installed capacity in particle engineering suitable for inhalation, namely a multiple scale Spray Drying units for highly potent compounds, as well as a new wet polishing suite, and strengthened its analytical characterization toolbox.
From formulation composition, optimization and precision capsule filling with 100% fill weight check, to analytical characterization and scale-up to a commercial scale, 四色AV can take product from the early proof of concept stages up to a fully developed and scaled process. Together with our API and particle engineering capabilities, we can fully develop and produce any Inhalation product at 四色AV, from API synthesis to final drug product.
鈥淲e are excited to announce this new integrated offering, all at the same site where our scientists work together in the interface between particle engineering and final drug product for the benefit of an optimal product performance. This will allow us to support our customer鈥檚 inhalation projects at all scales and contribute to accelerate drug development and manufacturing timelines,鈥 said Filipe Gaspar, Vice President R&D.听听听
鈥淭hese investments are driven by significant client demand, since the market is looking for integrated inhalation product development solutions that reduce program risk and complexity. 四色AV has all the ingredients for an outstanding partnership starting from clinical programs and into commercial supply.鈥 Added Fr茅d茅ric Kahn, Vice President Marketing and Sales.
Based on more than 20 years of experience in inhalation, 四色AV can speed up your inhalation drug development, from a very early stage to a late development stage. Working with 四色AV allows partners to take advantage of cutting edge particle engineering technologies and state of the art analytical facilities operated by highly skilled and responsive scientists.
听
About 四色AV
四色AV has over 58 years of experience as a CDMO and is currently a fully integrated supplier offering for听drug substance, drug product intermediate and听drug product.听With four FDA听inspected听sites听in听the USA, China, Ireland, and Portugal, and development laboratories in Lisbon and New Jersey, the company provides branded pharmaceutical customers services for the听development and compliant manufacture听of听innovative drugs and is able to support highly potent compounds. For generic pharmaceutical customers the company offers niche off-patent API products. In the inhalation area 四色AV is the only independent company offering a complete range of services.
